Targets › FGF19
2 programs from 2 companies in 5 trials: 3 Phase 1, 2 Phase 2; Oncology, Other; next expected readout Jun 2027.
Involved in the suppression of bile acid biosynthesis through down-regulation of CYP7A1 expression, following positive regulation of the JNK and ERK1/2 cascades. Stimulates glucose uptake in adipocytes. (UniProt, O95750)
Open in Phaseline: the race on FGF19, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Abbisko Therapeutics | ABSK-011 Capsules FGF19 inhibitor | FGF19 | Phase 2 | Hepatocellular Carcinoma (HCC); Healthy Participants; Advanced Liver Cancer; HCC - Hepatocellular Carcinoma | Jun 2027 |
| Huahui Health | HH-009 FGF19 antagonist | FGF19 | Phase 1 | Advanced or Unresectable Hepatocellular Carcinoma (HCC) | Oct 2028 |
Hepatocellular Carcinoma (HCC) (1) Healthy Participants (1) Advanced Liver Cancer (1) HCC - Hepatocellular Carcinoma (1) Advanced or Unresectable Hepatocellular Carcinoma (HCC) (1)
small molecule (2)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.